Berberine

Studies of berberine in people

38 studies gave berberine to people and measured what changed

What changedDesignPeopleSource

no change: Has no effect on visceral adipose tissue area1.38% [97.5% CI, −2.43% to 5.18%]

no change: Has no effect on liver fat content0.87% [97.5% CI, −0.39% to 2.13%]

down: Decreases low-density lipoprotein cholesterol−7.72 [95% CI, −13.13 to −1.93] mg/dL

Randomized trial6 months337 people116 (34.4%) were female, and 221 (65.6%) were malemean (SD) age was 41.8 (10.6) yearsDiabetes-free individuals with obesity and MASLDJAMA network open, Jan 2, 2026

up: Increases VEGFA

down: Decreases pulse wave analysis systolic pressure134.85 ± 16.26 before and 124.46 ± 13.47 after

no change: Has no effect on arterial stiffness

Randomized trial12 weeks70 people40 to 60 yearsPatients with MAFLDNutrients, Nov 16, 2025

down: Decreases colorectal adenoma recurrenceadjusted HR 0.58, 95% CI 0.45–0.74

down: Decreases colorectal neoplasm occurrenceadjusted HR 0.75, 95% CI 0.62–0.91

Treated cohort2 years648 peoplePatients aged 18–75 years who had undergone endoscopic polypectomy six months before recruitmentCell reports. Medicine, Aug 11, 2025

down: Decreases homeostatic model assessment of insulin resistance0.51 ≤ ES ≤0.54

Randomized trial8 weeks64 peoplemenmiddle-agedMiddle-aged men with overweight or obesity and varying glycemic levelsPhysiological reports, Aug 1, 2024

down: Decreases alanine transaminasep=0.0105

down: Decreases de Ritis ratiop=0.0011

down: Decreases total cholesterolp=0.0009

Randomized trial12 weeks70 peopleMAFLDJournal of physiology and pharmacology : an official journal of the Polish Physiological Society, Jul 18, 2024

down: Decreases blood pressure

down: Decreases body weight

Randomized trial3 months50 peopleadultPatients diagnosed with exogenous obesityNutrients, Jul 16, 2024

down: Decreases fasting blood glucose5.33 ± 0.28 vs 6.16 ± 0.44 mmol/L

down: Decreases HOMA-IR2.41 ± 0.14 vs 3.40 ± 0.28 units

Randomized trial84 days34 peopleIndividuals with prediabetes fulfilling the inclusion and exclusion criteriaBMC endocrine disorders, Sep 7, 2023

down: Decreases body weight

down: Decreases TNF-alpha

Randomized trial20 weeks43 peoplePeople living with HIV under virological suppression and metabolic syndromeInternational journal of STD & AIDS, Aug 23, 2023

down: Decreases glycemiaβ=-0.2495 (95% CI -0.47; -0.06), p=0.004

down: Decreases total cholesterolβ=-0.25 (95% CI -0.45; -0.04), p=0.05

down: Decreases visceral adipose tissueβ=-91.50 (95% CI -132.60; -48.19), p<0.0001

Randomized trialtwo months49 peopleBothIn overweight subjects with impaired fasting blood glucose, versus placeboEuropean review for medical and pharmacological sciences, Jul 1, 2023

down: Decreases body weightMD -1.08, 95% CI -1.76 to -0.40, P = 0.002, d = 0.59

down: Decreases total cholesterolMD -0.58, 95% CI -0.74 to -0.41, P < 0.001, d = 1.31

Randomized trial12 weeks113 peopleSchizophrenia spectrum disorders with metabolic syndromePsychiatry and clinical neurosciences, Jan 18, 2022

down: Decreases body weight-1.10 kg vs +1.45 kg, P = 0.001

down: Decreases leptinFtime*group=6.265, P = 0.003

no change: Has no effect on adiponectin

Randomized trial8-week49 peopleIn patients with schizophrenia on stable antipsychotic treatmentAsian journal of psychiatry, Nov 1, 2021

up: Increases insulin secretion

no change: Has no effect on basal insulin secretion

Randomized trial160-min clamp, 14-day follow up15 peopleMenGeneral population; under hyperglycemic state during hyperglycemic clampNature communications, Sep 23, 2021

down: Decreases fasting plasma glucoseLS mean difference −0.50 mmol/L (95% CI −0.85 to −0.15)

Randomized trial16 weeks297 people18-70 yearsNewly diagnosed patients with hyperglycemiaGenome medicine, Aug 9, 2021

down: Decreases total cholesterol

down: Decreases HDL-C

no change: Has no effect on blood pressure

Randomized trial12 weeks84 peoplemen20 to 65 yearsEligible menNutrients, Jul 26, 2021

down: Decreases total cholesterolall p<0.05

down: Decreases low-density lipoprotein cholesterolall p<0.05

down: Decreases insulin resistanceall p<0.05

Randomized trial8 weeks49 peopleAdjunctive treatmentPsychiatry research, Mar 23, 2021

down: Decreases HOMA-IR

Randomized trial12 weeks132 peopleMild metabolic disorders induced by olanzapineThe American journal of Chinese medicine, Jan 1, 2021

down: Decreases HbA1c−0.99 [−1.16, −0.83]% vs −0.59 [−0.75, −0.44]%

up: Increases gastrointestinal side effects

Randomized trial12 weeks409 peopleParticipants with newly diagnosed type 2 diabetes who were drug naive for glycemic control with at least 2 months of stable lifestyle interventionNature communications, Oct 6, 2020

down: Decreases total cholesterol

Randomized trial90 days12 people30-60 yearsMidlife adults; mixed dyslipidemiaJournal of medicinal food, May 12, 2020

down: Lowers the risk of colorectal adenoma recurrenceRR 0.77 (95% CI 0.66-0.91), 36% vs 47%

up: Increases constipation1% vs <0.5%

Randomized trialup to 2 years18-75 yearsGeneral population; Midlife adults; Older adults; after complete polypectomy of colorectal adenomasThe lancet. Gastroenterology & hepatology, Jan 8, 2020

down: Decreases Geboes grade

Randomized trial3 monthsOn mesalamineCancer prevention research (Philadelphia, Pa.), Oct 16, 2019

up: Increases brown adipose tissue mass and activity

down: Decreases body weight

up: Improves insulin sensitivity

Trial1 monthMildly overweight patients with non-alcoholic fatty liver diseaseCell death & disease, Jun 13, 2019

down: Decreases urine albumin-creatinine ratio47(26, 120) mg/g vs 68(28, 158) mg/g, P=0.039

down: Decreases cystatin C(0.83±0.30) mg/L vs (0.96±0.30)mg/L, P=0.041

down: Protects against diabetic kidney disease

Randomized trialsix months114 peopleBoth(55±14) yearsMidlife adults; type 2 diabetes mellitusZhonghua yi xue za zhi, Dec 11, 2018

down: Decreases total cholesterol

Randomized trial3 successive months97 peopleMild hyperlipidemiaZhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, Jun 1, 2016

down: Decreases hepatic fat52.7% vs 36.4%

down: Decreases body weightp<0.05

down: Decreases HOMA-IRp<0.05

Randomized trial16 weeks184 peoplePatient cohortsPloS one, Aug 7, 2015

up: Improves pregnancy rate

down: Lowers the risk of severe ovarian hyperstimulation syndrome

up: Improves live birth rate

Randomized trial3 months150 peopleWomenIn infertile women with PCOS undergoing IVF treatmentClinical endocrinology, Aug 9, 2013

down: Decreases metabolic syndromeremission of 36% (P=0.037)

up: Improves insulin sensitivity2.1±1.0 vs. 3.1±1.6, P<0.01

down: Decreases total insulin secretion92,056±72,148 vs. 67,407±46,441 pmol/L, P<0.01

Randomized trial3 months24 peopleBothPatients with metabolic syndromeMetabolic syndrome and related disorders, Jun 28, 2013

down: Decreases LDL cholesterol

up: Increases HDL cholesterol

Randomized trial3 months144 peopleGeneral populationExpert opinion on biological therapy, Feb 27, 2013

down: Decreases LDL cholesterol

Randomized trialsix months270 peopleSubjects with primary polygenic HCH who had a negative history of cardiovascular disease and were previously found to be intolerant to STs or were refusing treatment with these drugsLipids in health and disease, Sep 22, 2012

down: Decreases body weightaverage 5 lb/subject

down: Decreases blood lipids23% decrease of triglyceride and 12.2% decrease of cholesterol levels

Trial12 weeksObesePhytomedicine : international journal of phytotherapy and phytopharmacology, Jun 26, 2012

down: Decreases MMP9

Trial30 days130 peopleIn ACS patients following PCIClinical and experimental pharmacology & physiology, May 1, 2012

down: Decreases metabolic dysfunction-associated steatotic liver disease70% effective rate

down: Decreases alanine aminotransferase

down: Decreases total cholesterol

Randomized trial12 weeks60 peopleNew diagnosed type 2 diabetes combining nonalcoholic fatty liver diseaseZhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, Nov 1, 2011

down: Decreases waist circumferenceP<0.01

down: Decreases low-density lipoprotein cholesterolP<0.05

down: Decreases homeostasis model assessment for IRP<0.05

Randomized trial3 months89 peopleWomenIn women with PCOS and IR receiving compound cyproterone acetateEuropean journal of endocrinology, Oct 21, 2011

down: Decreases free fatty acids

Randomized trial60 peopleType 2 diabetes and dyslipidemiaTalanta, Jan 18, 2010

down: Decreases fasting blood glucose

Randomized trialType 2 diabetes mellitusMetabolism: clinical and experimental, Oct 1, 2009

down: Decreases CD31+/CD42- microparticles

up: Improves flow-mediated vasodilation

no change: Has no effect on nitroglyceride-mediated vasodilation

Trial1-month14 peopleGeneral populationEuropean journal of pharmacology, May 3, 2009

down: Decreases HbA1cfrom 9.5%+/-0.5% to 7.5%+/-0.4%, P<.01

down: Decreases triglyceridefrom 1.13+/-0.13 to 0.89+/-0.03 mmol/L, P<.05

down: Decreases HOMA-IRreduced by 44.7% (P<.001)

Randomized trial3 months36 peopleNewly diagnosed type 2 diabetes mellitusMetabolism: clinical and experimental, May 1, 2008

down: Decreases HbA1cHbA1c from 7.5 +/- 1.0% to 6.6 +/- 0.7%, P < 0.0001 vs placebo

down: Decreases LDL cholesterolfrom 3.23 +/- 0.81 to 2.55 +/- 0.77 mm/liter, P < 0.0001 vs placebo

no change: Has no effect on insulin sensitivityP = 0.063 vs placebo

Randomized trial3 months116 peopleIn type 2 diabetic patients with dyslipidemiaThe Journal of clinical endocrinology and metabolism, Apr 8, 2008

down: Decreases LDL cholesterol-25%

Trial3 months32 peopleHypercholesterolemiaNature medicine, Nov 7, 2004